Day: May 10, 2022

Posted on

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Lucid Group, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – LCID

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Lucid Group, Inc. (NASDAQ: LCID) between November 15, 2021 and February 28, 2022, inclusive (the “Class Period”), of the important May 31, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Lucid securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Lucid class action, go to https://rosenlegal.com/submit-form/?case_id=4992 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 31, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business and operations. Specifically, Defendants overstated Lucid’s production capabilities while concealing that “extraordinary supply chain and logistics challenges” were already significantly hampering the Company’s operations. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lucid class action, go to https://rosenlegal.com/submit-form/?case_id=4992 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Posted on

ROSEN, LEADING INVESTOR COUNSEL, Encourages Cano Health, Inc. f/k/a Jaws Acquisition Corp. Investors with Losses to Secure Counsel Before Important May 17 Deadline in Securities Class Action – CANO, CANO.WS, JWS, JWS.U, JWS WS

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cano Health, Inc. f/k/a Jaws Acquisition Corp. (NYSE: CANO, CANO.WS, JWS, JWS.U, JWS WS) between May 18, 2020 and February 25, 2022, inclusive (the “Class Period”), of the important May 17, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Cano Health securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Cano Health class action, go to https://rosenlegal.com/submit-form/?case_id=4271 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Cano Health overstated its due diligence efforts and expertise with respect to acquiring target businesses; (2) accordingly, Cano Health performed inadequate due diligence into whether the Company, post-Business Combination, could properly account for the timing of revenue recognition as prescribed by ASC 606, particularly with respect to Medicare risk adjustments; (3) as a result, Cano Health misstated its capitated revenue, direct patient expense, accounts receivable, net of unpaid service provider costs, and accounts payable and accrued expenses; (4) accordingly, Cano Health was at an increased risk of failing to timely file one or more of its periodic financial reports; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Cano Health class action, go to https://rosenlegal.com/submit-form/?case_id=4271 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Posted on

ROSEN, LEADING INVESTOR COUNSEL, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important May 24 Deadline in Securities Class Action – FIXX

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”), of the important May 24, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Homology securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Homology class action, go to https://rosenlegal.com/submit-form/?case_id=4851 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 24, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Homology had overstated the efficacy and risk mitigation regarding HMI-102, which is in Phase I/II pheNIX clinical trial and a gene therapy for the treatment of phenylketonuria (PKU) in adults; (2) accordingly, it was unlikely that Homology would be able to commercialize HMI-102 in its present form; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Homology class action, go to https://rosenlegal.com/submit-form/?case_id=4851 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Posted on

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages International Business Machines Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – IBM

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of International Business Machines Corporation (NYSE: IBM) between April 4, 2017 and October 20, 2021, inclusive (the “Class Period”), of the important June 6, 2022 lead plaintiff deadline.

SO WHAT: If you purchased IBM securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the IBM class action, go to https://rosenlegal.com/submit-form/?case_id=5104 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 6, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Strategic Imperatives Revenue and growth, CAMSS (the sectors of “Cloud,” “Analytics,” “Mobile,” “Security,” and “Social”) and CAMSS Components’ revenue and growth, and the Company’s Segments’ revenue and growth were artificially inflated as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives Revenue; (2) IBM’s present success and positive future growth prospects concerning its Strategic Imperative business strategy were being fueled by the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperative Revenue; (3) as a result of the foregoing, defendants misled the market by portraying IBM’s Strategic Imperative’s financial performance and future prospects more favorable than they actually were as a result of the fraudulent scheme and/or the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives; and (4) Total Revenue and IBM’s Segments’ revenue and growth were artificially inflated as a result of the fraudulent scheme and/or the wrongful reclassification of revenues from non-strategic to strategic and/or the wrongful recognition of revenue. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the IBM class action, go to https://rosenlegal.com/submit-form/?case_id=5104 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Posted on

Nyxoah Reports First Quarter 2022 Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports First Quarter 2022 Financial and Operating Results

Mont-Saint-Guibert, Belgium – May 9, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2022.

First Quarter 2022 Financial and Operating Highlights

  • Generated revenue of €660,000 from the commercialization of Genio® in Europe, primarily in Germany, which represents year-over-year growth of more than three-and-and-half times and is more than double what was achieved in the fourth quarter of 2021
  • Exited the first quarter with 15 active implant sites in Germany, representing 25% growth over Q4 2021; Nyxoah expects to add an extra 10 sites by the end of the third quarter of 2022, bringing the total to 25 active implanting accounts and driving quarterly sales acceleration and market leadership in Germany by the end of 2022
  • Completed the first commercial Complete Concentric Collapse (CCC) patients in Germany
  • Accelerated monthly patient enrollment in the DREAM U.S. IDE study and continue to expect implants to be completed in the second quarter of 2022
  • The U.S. FDA approved Nyxoah’s request to reduce the sample size in DREAM to 115 patients from the original 134, driven by new and favorable data from the BETTER SLEEP study; aside from the updated sample size, all other study parameters, including performance goals, statistical power, and significance level, remain identical to the original approved study
  • Nominated Raymond Cohen, Chief Executive Officer and board member of Axonics, Inc. and Virginia Kirby, Executive-in-Residence at the Discovery Launchpad at the University of Minnesota’s Office of Technology Commercialization, for appointment to the Board of Directors, pending approval by the Annual Shareholders’ Meeting on June 8, 2022; Don Deyo and Jan Janssen are stepping down, keeping the total number of board members at eight

“I am extremely pleased with our first quarter results and strong execution that resulted in an acceleration in sales and DREAM implants as we progress towards achieving all of our strategic priorities for 2022 and beyond,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “On the commercial side, the €660,000 of revenue we booked in the first quarter was roughly equal to the revenue performance from the previous three quarters combined. We now have 15 active implant sites in Germany, and we will continue to add 10 more sites by the end of the third quarter. This growth validates our patient-centric, ‘Going Deep’ strategy of developing Centers of Excellence as we increase therapy penetration at each of these sites. We were also thrilled to implant our first commercial CCC patients in Germany, and we expect continued acceleration in CCC implants following the positive response to our BETTER SLEEP data presentation at the World Sleep Congress in Rome, where we hosted 55 key opinion leaders during the pre-Congress symposium.”

Mr. Taelman continued, “We are also happy with the acceleration in the pace of implants in our DREAM U.S. pivotal study, given recent weekly implant rates, which have increased meaningfully over the last month. We believe we have enough patients enrolled to complete the study by the end of the second quarter of 2022, particularly in light of the FDA’s approval to reduce the sample size to 115 patients. We also continue our dialogue with FDA regarding our IDE submission for our ACCCESS trial for CCC patients in the U.S., and we expect to implant our first patient before the end of this year.”

“Finally, I am thrilled to announce the nominations of Ray Cohen and Ginny Kirby for appointment to the Board of Directors. They will bring a wealth of knowledge that will benefit Nyxoah as we complete DREAM, prepare for our U.S. launch, and advance our pipeline. I look forward to working closely with both of them,” concluded Mr. Taelman.

First Quarter 2022 Results

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS AT AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 – INTERIM CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS

 (unaudited) (in thousands)

For the three months ended March 31
Notes 2022 2021
Revenue €  660 €  185
Cost of goods sold ( 289) ( 52)
Gross profit €  371 €  133
Research and Development Expense (3 595) (3 094)
Selling, General and Administrative Expense (4 193) (2 366)
Other income/(expense) 136 4
Operating loss for the period € (7 281) € (5 323)
Financial income 1 576 4
Financial expense ( 788) ( 325)
Loss for the period before taxes € (6 493) € (5 644)
Income taxes ( 208) ( 25)
Loss for the period € (6 701) € (5 669)
Loss attributable to equity holders € (6 701) € (5 669)
Other comprehensive loss
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences ( 102) ( 70)
Total comprehensive loss for the year, net of tax € (6 803) € (5 739)
Loss attributable to equity holders € (6 803) € (5 739)
Basic Loss Per Share (in EUR) € (0.260) € (0.256)
Diluted Loss Per Share (in EUR) € (0.260) € (0.256)

The accompanying notes are an integral part of these condensed consolidated interim financial statements

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS AT AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 – INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited) (in thousands)

For the three months ended March 31
2022 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax for the year € (6 493) € (5 644)
Adjustments for
Finance income (1 576) ( 4)
Finance expenses 788 325
Depreciation and impairment of property, plant and equipment and right-of-use assets 255 164
Amortization of intangible assets 208 211
Share-based payment transaction expense 665 −
Increase/(decrease) in provisions 10 −
Other non-cash items 180 3
Cash generated before changes in working capital € (5 963) € (4 945)
Changes in working capital
Decrease/(Increase) in inventory 45 ( 51)
(Increase)/decrease in trade and other receivables 884 (1 195)
Increase/(Decrease) in trade and other payables ( 392) 2 170
Cash generated from changes in operations € (5 426) € (4 021)
Interests received − 1
Income tax paid (65) (34)
Net cash used in operating activities € (5 491) € (4 054)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment ( 128) ( 169)
Capitalization of intangible assets (3 412) (1 606)
(Increase)/decrease in financial assets – current (44 032) −
Net cash used in investing activities € (47 572) € (1 775)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of principal portion of lease liabilities ( 146) ( 135)
Repayment of other loan ( 21) ( 21)
Interests paid ( 109) ( 105)
Proceeds from issuance of shares, net of transaction costs 130 52
Other financial costs (2) −
Net cash generated from financing activities € ( 148) € ( 209)
Movement in cash and cash equivalents € (53 211) € (6 038)
Effect of exchange rates on cash and cash equivalents 489 ( 55)
Cash and cash equivalents at January 1 € 135 509 € 92 300
Cash and cash equivalents at March 31 € 82 787 € 86 207

Revenue

Revenue was €660,000 for the first quarter ending March 31, 2022, compared to €185,000 for the first quarter ending March 31, 2021. The increase in revenue was attributable to the Company’s commercialization of the Genio® system, primarily in Germany.

Cost of Goods Sold

Cost of goods sold was €289,000 for the three months ending March 31, 2022, representing a gross profit of €371,000, or gross margin of 56.2%.

Research and Development Expenses

Research and Development expenses were €3.6 million for the three months ending March 31, 2022, versus €3.1 million for the prior year period, reflecting the Company’s investments in the development of next generation versions of the Genio® system as well as ongoing clinical studies, most notably DREAM in the U.S.

Selling, General and Administrative Expenses

General and administrative expenses rose to €4.2 million for the first quarter of 2022, up from €2.4 million in the first quarter of 2021. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah’s corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of U.S. commercial launch.

Operating Loss

Total operating loss for the first quarter of 2022 was €7.3 million versus €5.3 million in the first quarter of 2021, driven by the acceleration in our R&D spending, as well as ongoing commercial and clinical activities. Nyxoah realized a net loss of €6.7 million for the quarter ended March 31, 2022, compared to a net loss of €5.7 million for the quarter ended March 31, 2021.

Cash Position
As of March 31, 2022, cash and financial assets totaled €127.8 million on March 31, 2022, compared to €135.5 million on December 31, 2021. Total cash burn was approximately €2.6 million per month during the first quarter of 2022. Nyxoah expects monthly cash burn to increase slightly as the year progresses to account for the commencement of the ACCCESS IDE trial in the U.S., and current cash position provides ample liquidity to get to U.S. commercialization in 2024.

First Quarter 2022 Report
Nyxoah’s financial report for the first quarter of 2022, including details of the consolidated results, are available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation 
Nyxoah will conduct a conference call open to the public tomorrow, May 10, 2022, at 2:00 p.m. CET / 8:00 a.m. ET, which will also be webcasted. To participate in the conference call, please dial one of the following numbers:

Conference ID: 8444917

USA:                             (844) 260-3718
Belgium:                       0800 73264
International:                (929) 517-0938

A question-and-answer session will follow the presentation of the results. To access the live webcast, go to https://investors.nyxoah.com/events. The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements 
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, to be filed with the Securities and Exchange Commission (“SEC”) on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com

+1 917 749 1494

Attachment

Posted on

Synchronoss to Provide Wholesale Process Automation and Management to Brightspeed

Relationship to Support Brightspeed’s Planned Fiber Deployments Across 20-State Footprint

Multi-Year Agreement Features interconnectNOW and Financial Analytics
to Help Orchestrate Service Requests and Manage Trading Partner Expense

BRIDGEWATER, N.J., May 09, 2022 (GLOBE NEWSWIRE) — Synchronoss Technologies Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader and innovator in cloud, messaging and digital products and platforms, today announced that it has signed a multi-year agreement with Brightspeed, a provider of broadband and telecommunications services expected to have operations in 20 States. Brightspeed will initially be comprised of the incumbent local exchange carrier (ILEC) assets and associated operations of Lumen Technologies (NYSE: LUMN), which are the subject of a pending acquisition by Apollo-managed funds (NYSE: APO).

Brightspeed will utilize two key modules from the Synchronoss networkX Platform – interconnectNOW (iNOW) and Financial Analytics (FA) – for its planned fiber deployments throughout its multi-state territory across rural and suburban regions of the United States.

Brightspeed previously announced plans to invest more than $2 billion to build a network that will bring faster, more reliable Internet and Wi-Fi to communities throughout the Midwest, Southeast, and certain parts of Pennsylvania and New Jersey.   The company’s planned fiber optics transformation is expected to reach up to three million homes and businesses over the next five years, including in many places where fiber and advanced technology have not historically been deployed.

“As Brightspeed continues to build out its fiber optics network, iNOW and Financial Analytics will be integral in managing the company’s wholesale carrier operations,” said Chris Hill, Chief Commercial Officer at Synchronoss. “Automating and orchestrating orders throughout the lifecycle will enable Brightspeed to keep pace with customer requests and realize revenue faster.”

“Our partnership with Synchronoss will provide us access to their state-of-the-art platforms to achieve exceptional efficiencies in managing our wholesale carrier orders and trading partner transactions,” said Chris Creager, Chief Administration Officer of Brightspeed. “From end-to-end, iNOW will enable us to track orders and help us deliver world-class connectivity products and services to the communities we look forward to serving.”

The iNOW platform eliminates manual handling of service orders and manages the full lifecycle between customer and supplier via automation and rules-based validation. It provides a single interface and database for all buyer and supplier orders, making it easy to track orders from receipt to fulfillment, reconciles billing, and provides real-time reporting – shortening time to revenue.

The Financial Analytics platform streamlines the management of complex carrier invoicing via automated workflow and intuitive rules engines for auditing, accounting, validation, and payment of invoices. FA empowers service providers such as Brightspeed with the necessary tools and processes to ensure intercarrier expenses are thoroughly analyzed and confirmed prior to payment.

Leading service providers from around the world utilize Synchronoss and the iNOW platform to manage 39 million orders and transactions annually from 5,000 integrated operators.

About Synchronoss

Synchronoss Technologies (Nasdaq: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company’s collection of products helps streamline networks, simplify onboarding, and engage subscribers to unleash new revenue streams, reduce costs and increase speed to market. Hundreds of millions of subscribers trust Synchronoss products to stay in sync with the people, services, and content they love. That’s why more than 1,500 talented Synchronoss employees worldwide strive each day to reimagine a world in sync. Learn more at www.synchronoss.com.

About Brightspeed

Headquartered in Charlotte, N.C. and expected to have assets and associated operations in 20 states, Brightspeed will provide broadband and telecommunications services through a network platform capable of serving more than six million homes and businesses. The company aims to bridge the digital divide by deploying a state-of-the-art fiber network and a customer experience that makes staying connected simple and seamless. Learn more at www.brightspeed.com.

Synchronoss

Media Relations Contact:
Domenick Cilea
Springboard
dcilea@springboardpr.com

Investor Relations Contact:
Matt Glover / Tom Colton
Gateway Group, Inc.
SNCR@gatewayir.com

Brightspeed

Media Relations Contact:
Erik Carlson
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
pr@brightspeed.com

Posted on

یونیورسٹی آف ٹیکنالوجی سڈنی مئی میں ورچوئل اوپن ویک کا انعقاد کرے گی

سڈنی، 10 مئی 2022 /پی آر نیوز وائر/ — یونیورسٹی آف ٹیکنالوجی سڈنی (یو ٹی ایس) میں انٹرنیشنل ورچوئل اوپن ویک کے لئے رجسٹریشن اب کھل گئی ہے۔ توقع ہے کہ اس چار روزہ ایونٹ سے اعلیٰ تعلیم کی مانگ میں اضافہ ہوگا کیونکہ بین الاقوامی طلبہ دو سال کی سخت سرحدی بندش کے بعد آسٹریلیا واپس آ رہے ہیں۔

https://mma.prnewswire.com/media/1810543/UTS_student_Akash_Arora_journalism_sqr.jpg

یونیورسٹی آف ٹیکنالوجی سڈنی کے بین الاقوامی طالب علم آکاش اروڑا نے یو ٹی ایس اسکول آف کمیونیکیشن سے گریجویشن کرنے کے بعد آسٹریلیا کی معروف اشاعتوں میں کام کیا

اس پروگرام میں یونیورسٹی کی معروف ترین فیکلٹیز اور اسکولوں بشمول فیکلٹی آف ہیلتھ اور اسکول آف کمیونیکیشن کے آن لائن ماسٹر کلاسز اور انفارمیشن سیشنز شامل ہیں۔ بین الاقوامی طلبہ کورسز کی ایک وسیع رینج کی تلاش کرسکتے ہیں جس میں اتنا پوٹینشل ہے کہ زندگی بھر کے کیریئر کی رہنمائی ہوسکتی ہے۔

گریجویٹ آکاش اروڑا یو ٹی ایس ڈگری کی اہمیت کی تصدیق کرسکتے ہیں۔ بھارت سے تعلق رکھنے والے ایک بین الاقوامی طالب علم اروڑا نے دوسال ہندوستان ٹائمز میں کام کرنے کے بعد یو ٹی ایس سے ماسٹر آف جرنلزم کرنے کا انتخاب کیا۔ وہ اپنے صحافتی تجربے کو رسمی بنانا چاہتے تھے وہ کہتے ہیں کہ یو ٹی ایس پروگرام باقی پروگرامز  سے کہیں بہتر تھا۔

اس ڈگری نے انہیں بنیادی مہارتوں سے آراستہ کیا، جس میں موثر خبریں لکھنے اور بہترین فیچر لکھنے کی صلاحیت کے ساتھ ساتھ ہتک عزت کے قانون سے متعلق سمجھ بھی شامل تھی۔ اس کورس نے انہیں مختلف خبروں کے ذرائع ابلاغ کے فارمیٹ میں موثر طریقے سے کام کرنے کے لئے بھی تیار کیا۔

گریجویشن کے بعد اروڑا نے ڈیلی ٹیلی گراف، کنٹاس میگزین اور گورمے ٹریولر سمیت معروف آسٹریلوی اشاعتوں کے علاوہ لندن اور نیویارک میں مختلف کرداروں میں 15 سال سے زائد عرصے تک پرنٹ جرنلسٹ کے طور پر کام کیا۔ آج وہ ڈیجیٹل صحافی اور آسٹریلوی نشریاتی ادارے ایس بی ایس کے ایڈیٹر ہیں۔

انہوں نے کہا کہ یو ٹی ایس نے مجھے جو کچھ سکھایا وہ پرنٹ جرنلزم نہیں تھا؛ اس نے مجھے اچھی صحافت سکھائی۔ اس کا مطلب یہ ہے کہ میں اچھی صحافت کا اطلاق کسی بھی ذرائع ابلاغ پر تھوڑی سی تربیت اور مطابقت کے ساتھ کر سکتا ہوں۔

اہم بات یہ ہے کہ یو ٹی ایس میں گزارے وقت نے اروڑا کو آسٹریلوی ثقافت سمجھنے میں بھی مدد کی۔

انہوں نے مزید کہا کہ صحافت میں، آپ کو واقعی اپنے سامعین کی نبض پکڑنے کے قابل ہونے کی ضرورت ہے اور یہ اس وقت مشکل ہوتا ہے جب آپ  ثقافتی باریکیوں کو نہیں سمجھتے ہیں۔

ان تمام سالوں میں یو ٹی ایس سے مجھے جو مہارتیں حاصل یوئیں ان سے مجھے ان لوگوں کے ساتھ بائی لائنز کا مقابلہ کرنے میں مدد ملی جو آسٹریلوی ثقافت اور منظر نامے سے  واقف تھے۔

یونیورسٹی آف ٹیکنالوجی سڈنی معلومات حاصل کریں اور یو ٹی ایس ورچوئل اوپن ویک (10–12 مئی 2022) میں دوسرے طلبا کی کامیابی کی کہانیاں سنیں۔ آج رجسٹر کریں۔

یو ٹی ایس کے بارے میں

یونیورسٹی آف ٹیکنالوجی سڈنی (یو ٹی ایس) ٹیکنالوجی کی ایک معروف یونیورسٹی اور آسٹریلیا کی نمبر ایک یونیورسٹی ہے۔ مزید معلومات کے لیے ملاحظہ کریں:  uts.edu.au

[1] QS Top 50 Under 50 2021

تصویری لنک:https://mma.prnewswire.com/media/1810543/UTS_student_Akash_Arora_journalism_sqr.jpg

 

Posted on

PM condemns attempts to drag institutions into politics

Prime Minister Shehbaz Sharif has condemned the attempts to drag institutions into politics saying the propaganda against institutions and the nefarious conspiracy to divide people into groups has been exposed.

The Prime Minister was expressed these views in a meeting of the parliamentary party of Pakistan Muslim League (Nawaz) in Islamabad.

Federal Ministers and Members of National Assembly belonging to PML-N attended the meeting.

The Prime Minister said it is responsibility of every Pakistani to fully defend Pakistan and national institutions against the sinister plan.

He said Pakistan was put back on the road to progress with the cooperation of allies of the government.

He said he was heading a government of allies who are working together for a bright future of Pakistan, leaving behind the past.

Prime Minister said it is my first meeting with the parliamentary party as Khadim e Pakistan.”

Shehbaz Sharif said the previous government, than had an artificial mandate, was defeated due to its arrogance and conceit.

He said a nefarious attempt was made to create chaos in the country with inflammatory statements and false propaganda.

He said strict action will be taken under the constitution and law against the provocative attempts.

He said during his visits to Saudi Arabia and United Arab Emirates, the hosts appreciated the international reputation of the present government.

Source: Radio Pakistan